Anti-LRRK2/Dardarin, C-Terminus Antibody (N241A/34)

Our Anti-Dardarin/LRRK2, C-terminus mouse monoclonal primary antibody from NeuroMab is produced in-house from hybridoma clone N241A/34. It is KO validated, detects drosophila, human, mouse, non-human primate, and rat Dardarin/LRRK2, C-terminus, and is purified by Protein A chromatography. It is great for use in IHC, ICC, IP, ELISA, WB.



SKU: 75-253

Volume: 100 µL
Price:
Sale price$374

Product Specific References for Applications and Species

ELISA: Human
PMID Dilution Publication
32652692not listedMelachroinou, K., et al. 2020. Elevated In Vitro Kinase Activity in Peripheral Blood Mononuclear Cells of Leucine-Rich Repeat Kinase 2 G2019S Carriers: A Novel Enzyme-Linked Immunosorbent Assay-Based Method. Movement Disorders, 2095-2100.
325235111 ug/ulMabrouk, O.S., et al. 2020. Quantitative Measurements of LRRK2 in Human Cerebrospinal Fluid Demonstrates Increased Levels in G2019S Patients. Frontiers in Neuroscience, .
320079611:10Padmanabhan, S., et al. 2020. An Assessment of LRRK2 Serine 935 Phosphorylation in Human Peripheral Blood Mononuclear Cells in Idiopathic Parkinson's Disease and G2019S LRRK2 Cohorts. NPJ Parkinson's Disease, 623-629.
30858560not listedSchaffner, A., et al. 2019. Vitamin B 12 modulates Parkinson's disease LRRK2 kinase activity through allosteric regulation and confers neuroprotection. Cell Research, 313-329.
Immunocytochemistry: Drosophila
PMID Dilution Publication
34250948not listedFellgett, A., et al. 2021. Multiple pathways of LRRK2-G2019S/Rab10 interaction in dopaminergic neurons.. Journal of Parkinson's Disease, 1805-1820.
Immunocytochemistry: Human
PMID Dilution Publication
369056281:3 (supe)Filippini, F., et al. 2023. Secretion of VGF Relies on the Interplay Between LRRK2 and Post-Golgi v-SNAREs. Cell Reports, 112221.
355994951:1000Fernández, B., et al. 2022. Evaluation of Current Methods to Detect Cellular Leucine-Rich Repeat Kinase 2 (LRRK2) Kinase Activity. Journal of Parkinson's Disease , 1423-1447.
346044461:1000Keeney, M.T., et al. 2021. Measurement of LRRK2 Kinase Activity by Proximity Ligation Assay. Bio-Protocol, e4140.
341146041mg/mlCalamini, B., et al. 2021. Development of a physiologically relevant and easily scalable LUHMES cell-based model of G2019S LRRK2-driven Parkinson's disease. Disease, Models, and Mechanisms, .
32359446not listedLee, H., et al. 2020. LRRK2 Is Recruited to Phagosomes and Co-recruits RAB8 and RAB10 in Human Pluripotent Stem Cell-Derived Macrophages. Stem Cell Reports, 940-955.
29472595not listedAntoniou, N., et al. 2018. A motif within the armadillo repeat of Parkinson's-linked LRRK2 interacts with FADD to hijack the extrinsic death pathway. Scientific Reports, 3455.
26651604not listedSchwab, A.J., et al. 2015. Neurite Aggregation and Calcium Dysfunction in iPSC-Derived Sensory Neurons with Parkinson''s Disease-Related LRRK2 G2019S Mutation.. Stem Cell Reports., 1039-1052.
Immunocytochemistry: Mouse
PMID Dilution Publication
355994951:50Fernández, B., et al. 2022. Evaluation of Current Methods to Detect Cellular Leucine-Rich Repeat Kinase 2 (LRRK2) Kinase Activity. Journal of Parkinson's Disease , 1423-1447.
31663853not listedBerndsen, K., et al. 2019. PPM1H phosphatase counteracts LRRK2 signaling by selectively dephosphorylating Rab proteins. Elife, e50416.
290548821:500Pan, P.Y., et al. 2017. Parkinson's Disease-Associated LRRK2 Hyperactive Kinase Mutant Disrupts Synaptic Vesicle Trafficking in Ventral Midbrain Neurons. Journal of Neuroscience, 11366-11376.
287104811:100Carrion, M.D.P., et al. 2017. The LRRK2 G2385R variant is a partial loss-of-function mutation that affects synaptic vesicle trafficking through altered protein interactions. Scientific Reports, 5377.
263653101:50Choi, I., et al. 2015. LRRK2 G2019S mutation attenuates microglial motility by inhibiting focal adhesion kinase.. Nature Communication, 8255.
Immunocytochemistry: Rat
PMID Dilution Publication
373844141:100Williamson, MG, et al. 2023. Mitochondrial Dysfunction and Mitophagy Defects in LRRK2-R1441C Parkinson's Disease Models. Human molecular genetics, 0.
355770651:1000Keeney, M.T., et al. 2022. NADPH oxidase 2 activity in Parkinson's disease. Neurobiology of Disease, 105754.
24927544not listedDaher, J.P., et al. 2014. Abrogation of α-synuclein-mediated dopaminergic neurodegeneration in LRRK2-deficient rats.. PNAS: USA, 9289-9294.
Immunohistochemistry: Human
PMID Dilution Publication
24633735not listedWest, A.B., et al. 2014. Differential LRRK2 expression in the cortex, striatum, and substantia nigra in transgenic and nontransgenic rodents.. Journal of Comparative Neurology, 2465-2480.
Immunohistochemistry: Mouse
PMID Dilution Publication
334835501:600Lebovitz, C., et al. 2021. Loss of Parkinson’s susceptibility gene LRRK2 promotes carcinogen-induced lung tumorigenesis. Scientific Reports, 2097.
309270721:1000Bieri, G., et al. 2019. LRRK2 modifies α-syn pathology and spread in mouse models and human neurons. Acta Neuropathologica Communications, 961-980.
279110061:100 - 1:400Dzamko, N., et al. 2017. LRRK2 levels and phosphorylation in Parkinson''s disease brain and cases with restricted Lewy bodies.. Movement Disorders, 423-432.
24633735not listedWest, A.B., et al. 2014. Differential LRRK2 expression in the cortex, striatum, and substantia nigra in transgenic and nontransgenic rodents.. Journal of Comparative Neurology, 2465-2480.
235607501:1000Davies, P., et al. 2013. Comprehensive characterization and optimization of anti-LRRK2 (leucine-rich repeat kinase 2) monoclonal antibodies.. Biochemical Journal, 101-13.
Immunohistochemistry: Rat
PMID Dilution Publication
355770651:500Keeney, M.T., et al. 2022. NADPH oxidase 2 activity in Parkinson's disease. Neurobiology of Disease, 105754.
336363871:500De Miranda, B.R., et al. 2021. The industrial solvent trichloroethylene induces LRRK2 kinase activity and dopaminergic neurodegeneration in a rat model of Parkinson's disease. Neurobiology of Disease, 105312.
24927544not listedDaher, J.P., et al. 2014. Abrogation of α-synuclein-mediated dopaminergic neurodegeneration in LRRK2-deficient rats.. PNAS: USA, 9289-9294.
24633735not listedWest, A.B., et al. 2014. Differential LRRK2 expression in the cortex, striatum, and substantia nigra in transgenic and nontransgenic rodents.. Journal of Comparative Neurology, 2465-2480.
235607501:1000Davies, P., et al. 2013. Comprehensive characterization and optimization of anti-LRRK2 (leucine-rich repeat kinase 2) monoclonal antibodies.. Biochemical Journal, 101-13.
Immunoprecipitation: Human
PMID Dilution Publication
32359446not listedLee, H., et al. 2020. LRRK2 Is Recruited to Phagosomes and Co-recruits RAB8 and RAB10 in Human Pluripotent Stem Cell-Derived Macrophages. Stem Cell Reports, 940-955.
235607501:1000Davies, P., et al. 2013. Comprehensive characterization and optimization of anti-LRRK2 (leucine-rich repeat kinase 2) monoclonal antibodies.. Biochemical Journal, 101-13.
Immunoprecipitation: Mouse
PMID Dilution Publication
29212815not listedPurlyte, E., et al. 2018. Rab29 activation of the Parkinson's disease-associated LRRK2 kinase. EMBO Journal, 1-18.
24282027not listedStafa, K., et al. 2014. Functional interaction of Parkinson''s disease-associated LRRK2 with members of the dynamin GTPase superfamily.. Human Molecular Genetics, 2055-2077.
PLA: Human
PMID Dilution Publication
346044461:500Keeney, M.T., et al. 2021. Measurement of LRRK2 Kinase Activity by Proximity Ligation Assay. Bio-Protocol, e4140.
PLA: Mouse
PMID Dilution Publication
355994951:1000Fernández, B., et al. 2022. Evaluation of Current Methods to Detect Cellular Leucine-Rich Repeat Kinase 2 (LRRK2) Kinase Activity. Journal of Parkinson's Disease , 1423-1447.
PLA: Rat
PMID Dilution Publication
346044461:500Keeney, M.T., et al. 2021. Measurement of LRRK2 Kinase Activity by Proximity Ligation Assay. Bio-Protocol, e4140.
Western Blot: Drosophila
PMID Dilution Publication
34250948not listedFellgett, A., et al. 2021. Multiple pathways of LRRK2-G2019S/Rab10 interaction in dopaminergic neurons.. Journal of Parkinson's Disease, 1805-1820.
340307271:200Sarkar, S., et al. 2021. Oligomerization of Lrrk controls actin severing and α-synuclein neurotoxicity in vivo. . Molecular Neurodegeneration, 44579.
323218361:1000Petridi, S., et al. 2020. In vivo visual screen for dopaminergic Rab↔ LRRK2-G2019S interactions in Drosophila discriminates Rab10 from Rab3.. Genes, Genomes, Genetics, 1903-1914.
292142111:1000Cording, A.C., et al. 2017. Targeted kinase inhibition relieves slowness and tremor in a Drosophila model of LRRK2 Parkinson's disease. NPJ Parkinson's Disease, 34.
Western Blot: Human
PMID Dilution Publication
371410991:1000Rinaldi, C., et al. 2023. Dissecting the Effects of GTPase and Kinase Domain Mutations on LRRK2 Endosomal Localization and Activity. Cell Reports, 112447.
360070111:1000Liu, X., et al. 2022. Discovery of XL01126: A Potent, Fast, Cooperative, Selective, Orally Bioavailable, and Blood-Brain Barrier Penetrant PROTAC Degrader of Leucine-Rich Repeat Kinase 2. Journal of American Chemical Society, .
353471441:1000Ahmadi Rastegar, D., et al. 2022. Effect of LRRK2 Protein and Activity on Stimulated Cytokines in Human Monocytes and Macrophages. NPJ Parkinson's Disease, 34.
353471441:1000Ahmadi Rastegar, D., et al. 2022. Effect of LRRK2 protein and activity on stimulated cytokines in human monocytes and macrophages. NPJ Parkinson's Disease, 34.
353264691ug/mlMarchand, A., et al. 2022. A Phosphosite Mutant Approach on LRRK2 Links Phosphorylation and Dephosphorylation to Protective and Deleterious Markers, Respectively. Cells, 1018.
35016853not listedCogo, S., et al. 2022. The Roc domain of LRRK2 as a hub for protein-protein interactions: a focus on PAK6 and its impact on RAB phosphorylation. Brain research, 147781.
345809801ug/mlWaschbüsch, D., et al. 2021. Structural basis for the specificity of PPM1H phosphatase for Rab GTPases. EMBO Reports, e52675.
34515301not listedTasegian, A., et al. 2021. Impact of Type II LRRK2 inhibitors on signaling and mitophagy. The Biochemical Journal, 3555-3573.
34315807not listedLiu, Q., et al. 2021. Dysregulation of the AP2M1 phosphorylation cycle by LRRK2 impairs endocytosis and leads to dopaminergic neurodegeneration. Science Signaling, eabg3555.
341453201:500Wang, X., et al. 2021. Understanding LRRK2 kinase activity in preclinical models and human subjects through quantitative analysis of LRRK2 and pT73 Rab10. Scientific Reports, 12900.
341252481ug/mlFan, Y., et al. 2021. R1441G but not G2019S mutation enhances LRRK2 mediated Rab10 phosphorylation in human peripheral blood neutrophils. Acta Neuropathologica Communications, 475-494.
341146041:1000Calamini, B., et al. 2021. Development of a physiologically relevant and easily scalable LUHMES cell-based model of G2019S LRRK2-driven Parkinson's disease. Disease, Models, and Mechanisms, .
34008015not listedCheung, M., et al. 2021. Novel LRRK2 mutations and other rare, non-BAP1-related candidate tumor predisposition gene variants in high-risk cancer families with mesothelioma and other tumors. Human Molecular Genetics, 1750-1761.
33938021not listedLai, D., et al. 2021. Genomewide Association Studies of LRRK2 Modifiers of Parkinson's Disease.. Annals of Neurology, 76-88.
338872261:1000Waschbüsch, D., et al. 2021. Dual arginine recognition of LRRK2 phosphorylated Rab GTPases. Biophysical Journal, 1846-1855.
33836114not listedBright, J.M., et al. 2021. Differential Inhibition of LRRK2 in Parkinson's Disease Patient Blood by a G2019S Selective LRRK2 Inhibitor. Movement Disorders, 1362-1371.
331971961:10,000Garofalo, A.W., et al. 2021. Selective Inhibitors of G2019S-LRRK2 Kinase Activity. Journal of Medicinal Chemistry, 14821-14839.
33049313not listedHarney, J., et al. 2021. An in vitro alveolar epithelial cell model recapitulates LRRK2 inhibitor-induced increases in lamellar body size observed in preclinical models. Toxicology In Vitro, 105012.
330571001:200Gonzalez-Hunt, C.P., et al. 2020. Mitochondrial DNA damage as a potential biomarker of LRRK2 kinase activity in LRRK2 Parkinson's disease. Scientific Reports, 17293.
328009981:1000Zhao, Y., et al. 2020. LRRK2 kinase inhibitors reduce alpha-synuclein in human neuronal cell lines with the G2019S mutation. Neurobiology of Disease, 105049.
32643832not listedHerbst, S., et al. 2020. LRRK2 activation controls the repair of damaged endomembranes in macrophages. EMBO Journal, e104494.
32461697not listedWhiffin, N., et al. 2020. The effect of LRRK2 loss-of-function variants in humans. Nature Medicine, 869-877.
32359446not listedLee, H., et al. 2020. LRRK2 Is Recruited to Phagosomes and Co-recruits RAB8 and RAB10 in Human Pluripotent Stem Cell-Derived Macrophages. Stem Cell Reports, 940-955.
32227113not listedVieweg, S., et al. 2020. PINK1-dependent phosphorylation of Serine111 within the SF3 motif of Rab GTPases impairs effector interactions and LRRK2-mediated phosphorylation at Threonine72.. Biochemical Journal, 1651-1668.
320178881:1000Waschbüsch, D., et al. 2020. Structural Basis for Rab8a Recruitment of RILPL2 via LRRK2 Phosphorylation of Switch 2. Structure, 406-417.
30858560not listedSchaffner, A., et al. 2019. Vitamin B 12 modulates Parkinson's disease LRRK2 kinase activity through allosteric regulation and confers neuroprotection. Cell Research, 313-329.
305976101:1000Atashrazm, F., et al. 2019. LRRK2-mediated Rab10 phosphorylation in immune cells from Parkinson's disease patients. Movement Disorders, 406-415.
30460108not listedJang, J., et al. 2018. Increase in anti-apoptotic molecules, nucleolin, and heat shock protein 70, against upregulated LRRK2 kinase activity. Animal Cells and Systems, 273-280.
29472595not listedAntoniou, N., et al. 2018. A motif within the armadillo repeat of Parkinson's-linked LRRK2 interacts with FADD to hijack the extrinsic death pathway. Scientific Reports, 3455.
293578971:1000Madero-Pérez, J., et al. 2018. Parkinson disease-associated mutations in LRRK2 cause centrosomal defects via Rab8a phosphorylation. . Molecular neurodegeneration, 44583.
29177506not listedLiu, Z., et al. 2018. LRRK2 phosphorylates membrane-bound Rabs and is activated by GTP-bound Rab7L1 to promote recruitment to the trans-Golgi network. Human Molecular Genetics, 385-395.
29166931not listedWang, S., et al. 2017. Elevated LRRK2 autophosphorylation in brain-derived and peripheral exosomes in LRRK2 mutation carriers. Acta Neuropathologica Communications, 86.
288604831:2000Thirstrup, K., et al. 2017. Selective LRRK2 kinase inhibition reduces phosphorylation of endogenous Rab10 and Rab12 in human peripheral mononuclear blood cells. Scientific Reports, 10300.
26251043not listedHenry, A.G., et al. 2015. Pathogenic LRRK2 mutations, through increased kinase activity, produce enlarged lysosomes with reduced degradative capacity and increase ATP13A2 expression.. Human Molecular Genetics, 6013-6028.
25939886not listedZhao, J., et al. 2015. LRRK2 dephosphorylation increases its ubiquitination. Biochemical Journal, 107-120.
250805041:1000Gómez-Suaga, P., et al. 2014. LRRK2 delays degradative receptor trafficking by impeding late endosomal budding through decreasing Rab7 activity.. Human Molecular Genetics, 6779-6796.
24633735not listedWest, A.B., et al. 2014. Differential LRRK2 expression in the cortex, striatum, and substantia nigra in transgenic and nontransgenic rodents.. Journal of Comparative Neurology, 2465-2480.
24427314not listedDorval, V., et al. 2014. Gene and MicroRNA transcriptome analysis of Parkinson''s related LRRK2 mouse models.. PLoS One, e85510.
235607501:1000Davies, P., et al. 2013. Comprehensive characterization and optimization of anti-LRRK2 (leucine-rich repeat kinase 2) monoclonal antibodies.. Biochemical Journal, 101-13.
230657051:15,000Yao, C., et al. 2013. Kinase inhibitors arrest neurodegeneration in cell and C. elegans models of LRRK2 toxicity.. Human Molecular Genetics, 328-344.
22012985not listedGómez-Suaga, P., et al. 2012. Leucine-rich repeat kinase 2 regulates autophagy through a calcium-dependent pathway involving NAADP.. Human Molecular Genetics, 511-525.
Western Blot: Mouse
PMID Dilution Publication
37289222not listedCabezudo, D, et al. 2023. Mutant LRRK2 Exacerbates Immune Response and Neurodegeneration in a Chronic Model of Experimental Colitis. Acta Neuropathologica, 245-261.
360402311:1000Malik, A.U., et al. 2022. PKC isoforms activate LRRK1 kinase by phosphorylating conserved residues (Ser1064, Ser1074 and Thr1075) within the CORB GTPase domain. Biochemical Journal, .
357766811:1000Lara Ordóñez, A.J., et al. 2022. The LRRK2 signaling network converges on a centriolar phospho-Rab10/RILPL1 complex to cause deficits in centrosome cohesion and cell polarization. Biology Open, .
355994951:1000Fernández, B., et al. 2022. Evaluation of Current Methods to Detect Cellular Leucine-Rich Repeat Kinase 2 (LRRK2) Kinase Activity. Journal of Parkinson's Disease , 1423-1447.
352694821:400Ho, D.H., et al. 2022. LRRK2 Inhibition Mitigates the Neuroinflammation Caused by TLR2-Specific α-Synuclein and Alleviates Neuroinflammation-Derived Dopaminergic Neuronal Loss. Cells, 861.
35012605not listedXu, E., et al. 2022. Pathological α-synuclein recruits LRRK2 expressing pro-inflammatory monocytes to the brain. Molecular neurodegeneration, 7.
34759048not listedKim, J.W., et al. 2021. Dysregulated mRNA Translation in the G2019S LRRK2 and LRRK2 Knock-Out Mouse Brains. eNeuro, .
34515301not listedTasegian, A., et al. 2021. Impact of Type II LRRK2 inhibitors on signaling and mitophagy. The Biochemical Journal, 3555-3573.
334593431:1000Malik, A.U., et al. 2021. Deciphering the LRRK code: LRRK1 and LRRK2 phosphorylate distinct Rab proteins and are regulated by diverse mechanisms. . Biochemical Journal, 553-578.
332989721:1000Wang, S., et al. 2020. Exosome markers of LRRK2 kinase inhibition. NPJ Parkinson's Disease, 32.
33135724not listedKalogeropulou, A.F., et al. 2020. Endogenous Rab29 does not impact basal or stimulated LRRK2 pathway activity. Biochemical Journal, 4397-4423.
32853409not listedLiu, Z., et al. 2020. LRRK2 and Rab10 coordinate macropinocytosis to mediate immunological responses in phagocytes. EMBO Journal, e104862.
328009981:1000Zhao, Y., et al. 2020. LRRK2 kinase inhibitors reduce alpha-synuclein in human neuronal cell lines with the G2019S mutatio. Neurobiology of Disease, .
32643832not listedHerbst, S., et al. 2020. LRRK2 activation controls the repair of damaged endomembranes in macrophages. EMBO Journal, e104494.
318812631:5 (supe)Kofoed, R.H., et al. 2020. Glycogen synthase kinase 3 β activity is essential for Polo-like kinase 2- and Leucine-rich repeat kinase 2-mediated regulation of α-synuclein. Neurobiology of Disease, 104720.
316638531:1000Berndsen, K., et al. 2019. PPM1H phosphatase counteracts LRRK2 signaling by selectively dephosphorylating Rab proteins. Elife, e50416.
30949397not listedHo, D.H., et al. 2019. G2019s LRRK2 promotes mitochondrial fission and increases TNFα-mediated neuroinflammation responses. Animal Cells and Systems, 106-111.
30592011not listedUlusoy, A., et al. 2019. Inhibition of LRRK2 or Casein Kinase 1 Results in LRRK2 Protein Destabilization. Molecular Neurobiology, 5273-5286.
300487141:2000Kelly, K., et al. 2018. The G2019S mutation in LRRK2 imparts resiliency to kinase inhibition. Experimental Neurology, 1-13.
30022868not listedHo, D.H., et al. 2018. LRRK2 Kinase Activity Induces Mitochondrial Fission in Microglia via Drp1 and Modulates Neuroinflammation. Experimental Neurobiology, 171-180.
297432031ug/mlMir, R., et al. 2018. The Parkinson's disease VPS35[D620N] mutation enhances LRRK2-mediated Rab protein phosphorylation in mouse and human. Biochemical Journal, 1861-1883.
29088368not listedNguyen, A.P.T., et al. 2018. G2019S LRRK2 enhances the neuronal transmission of tau in the mouse brain. Human Molecular Genetics, 120-134.
29246723not listedSchapansky, J., et al. 2017. Familial knockin mutation of LRRK2 causes lysosomal dysfunction and accumulation of endogenous insoluble α-synuclein in neurons. Neurobiology of Disease, 26-35.
279435911:500Qin, Q., et al. 2017. Effects of LRRK2 Inhibitors on Nigrostriatal Dopaminergic Neurotransmission. CNS Neuroscience and Therapeutics, 162-173.
279110061:1000Dzamko, N., et al. 2017. LRRK2 levels and phosphorylation in Parkinson''s disease brain and cases with restricted Lewy bodies.. Movement Disorders, 423-432.
26251043not listedHenry, A.G., et al. 2015. Pathogenic LRRK2 mutations, through increased kinase activity, produce enlarged lysosomes with reduced degradative capacity and increase ATP13A2 expression.. Human Molecular Genetics, 6013-6028.
25228699not listedLiu, Z., et al. 2014. Unique functional and structural properties of the LRRK2 protein ATP-binding pocket.. Journal of Biological Chemistry, 32937-32951.
24682598not listedSchapansky, J., et al. 2014. Membrane recruitment of endogenous LRRK2 precedes its potent regulation of autophagy.. Human Molecular Genetics, 4201-4214.
24633735not listedWest, A.B., et al. 2014. Differential LRRK2 expression in the cortex, striatum, and substantia nigra in transgenic and nontransgenic rodents.. Journal of Comparative Neurology, 2465-2480.
24427314not listedDorval, V., et al. 2014. Gene and MicroRNA transcriptome analysis of Parkinson''s related LRRK2 mouse models.. PLoS One., e85510.
Western Blot: Non-Human Primate
PMID Dilution Publication
25653221not listedFuji, R.N., et al. 2015. Effect of selective LRRK2 kinase inhibition on nonhuman primate lung.. Science Translastional Medicine, .
Western Blot: Rat
PMID Dilution Publication
35266954not listedStormo, A.E., et al. 2022. The E3 ligase TRIM1 ubiquitinates LRRK2 and controls its localization, degradation, and toxicity. Journal of Cell Biology, e202010065.
346583371:1000Khan, S.S., et al. 2021. Pathogenic LRRK2 control of primary cilia and Hedgehog signaling in neurons and astrocytes of mouse brain. Elife, e67900.
34306319not listedHo, D.H., et al. 2021. LRRK2 Kinase Inhibitor Rejuvenates Oxidative Stress-Induced Cellular Senescence in Neuronal Cells. Oxidative Medicine and Cell Longevity, 9969842.
33600829not listedKelly, K., et al. 2021. Genetic background influences LRRK2-mediated Rab phosphorylation in the rat brain. Brain Research, 147372.
335945321:200Van der Perren, A., et al. 2021. LRRK2 Ablation Attenuates Αlpha-Synuclein-Induced Neuroinflammation Without Affecting Neurodegeneration or Neuropathology In Vivo. Neurotherapeutics, 949-961.
326810501:2000Østergaard, F.G., et al. 2020. Classification of α-synuclein-induced changes in the AAV α-synuclein rat model of Parkinson's disease using electrophysiological measurements of visual processing. Scientific Reports, 11869.
32631998not listedNguyen, A.P.T., et al. 2020. Dopaminergic neurodegeneration induced by Parkinson's disease-linked G2019S LRRK2 is dependent on kinase and GTPase activity. PNAS: USA, 17296-17307.
31626293not listedShani, V., et al. 2019. Physiological and pathological roles of LRRK2 in the nuclear envelope integrity. Human Molecular Genetics, 3982-3996.
293075451:2000Andersen, M.A., et al. 2018. PFE-360-induced LRRK2 inhibition induces reversible, non-adverse renal changes in rats. Toxicology, 15-22.
259041071:1000Boddu, R., et al. 2015. Leucine-rich repeat kinase 2 deficiency is protective in rhabdomyolysis-induced kidney injury.. Human Molecular Genetics, 4078-4093.
251746491:1000Lee, J.W., et al. 2015. Behavioral, neurochemical, and pathologic alterations in bacterial artificial chromosome transgenic G2019S leucine-rich repeated kinase 2 rats.. Neurobiol Aging, 505-518.
24633735not listedWest, A.B., et al. 2014. Differential LRRK2 expression in the cortex, striatum, and substantia nigra in transgenic and nontransgenic rodents.. Journal of Comparative Neurology, 2465-2480.
235607501:1000Davies, P., et al. 2013. Comprehensive characterization and optimization of anti-LRRK2 (leucine-rich repeat kinase 2) monoclonal antibodies.. Biochemical Journal, 101-13.
Additional Publications: Unspecified
PMID Publication
34144124Drouyer, M., et al. 2021. Protein phosphatase 2A holoenzymes regulate leucine-rich repeat kinase 2 phosphorylation and accumulation. . Neurobiology of Disease, 105426.
32250352Fan, Y., et al. 2020. Human Peripheral Blood Neutrophil Isolation for Interrogating the Parkinson's Associated LRRK2 Kinase Pathway by Assessing Rab10 Phosphorylation. Journal of Visulized Experiments, .
31527116Fernández, B., et al. 2019. Centrosomal cohesion deficits as cellular biomarker in lymphoblastoid cell lines from LRRK2 Parkinson's disease patients. Biochemical Journal, 2797-2813.
31046837Lee, J.H., et al. 2019. Parkinson's disease-associated LRRK2-G2019S mutant acts through regulation of SERCA activity to control ER stress in astrocytes. Acta Neuropathologica Communications, 68.
30670570Leandrou, E., et al. 2019. Kinase activity of mutant LRRK2 manifests differently in hetero-dimeric vs. homo-dimeric complexes. Biochemical Journal, 559-579.
29519959Kalogeropulou, A.F., et al. 2018. P62/SQSTM1 is a novel leucine-rich repeat kinase 2 (LRRK2) substrate that enhances neuronal toxicity. Biochemical Journal, 1271-1293.
29127256Lis, P., et al. 2018. Development of phospho-specific Rab protein antibodies to monitor in vivo activity of the LRRK2 Parkinson's disease kinase. Biochemical Journal, 1-22.
29125462Steger, M., et al. 2017. Systematic proteomic analysis of LRRK2-mediated Rab GTPase phosphorylation establishes a connection to ciliogenesis. Elife, e31012.
29023112Williamson, D.S., et al. 2017. Design of Leucine-Rich Repeat Kinase 2 (LRRK2) Inhibitors Using a Crystallographic Surrogate Derived from Checkpoint Kinase 1 (CHK1). Journal of Medicinal Chemistry, 8945-8962.
28973664Howlett, E.H., et al. 2017. LRRK2 G2019S-induced mitochondrial DNA damage is LRRK2 kinase dependent and inhibition restores mtDNA integrity in Parkinson's disease. Human Molecular Genetics, 4340.
28321439Xiong, Y., et al. 2017. Overexpression of Parkinson's Disease-Associated Mutation LRRK2 G2019S in Mouse Forebrain Induces Behavioral Deficits and α-Synuclein Pathology. eNeuro, .
28115417Kim, M.J., et al. 2017. The Parkinson's disease-linked protein TMEM230 is required for Rab8a-mediated secretory vesicle trafficking and retromer trafficking. Human Molecular Genetics, 729-741.
27503089Perera, G., et al. 2016. Inhibitor treatment of peripheral mononuclear cells from Parkinson's disease patients further validates LRRK2 dephosphorylation as a pharmacodynamic biomarker. Scientific Reports, 31391.
27297049Fraser, K.B., et al. 2016. Ser(P)-1292 LRRK2 in urinary exosomes is elevated in idiopathic Parkinson's disease. Movement Disorders, 1543-1550.
26865512Fraser, K.B., et al. 2016. Urinary LRRK2 phosphorylation predicts parkinsonian phenotypes in G2019S LRRK2 carriers. Neurology, 994-999.

Related Products

Recently Viewed